Alzheimer's Disease: Unlocking the Secrets of Therapeutic Research
In the ever-evolving landscape of Alzheimer's disease (AD) research, a recent gathering at the Alzheimer Congress 2026 unveiled exciting developments and ongoing controversies. The speakers, Dr. Mathieu Ceccaldi and Dr. Davide Angioni, highlighted the central role of anti-amyloid immunotherapies and the promising yet uneven progress in therapeutic research.
The Promise of Sustained Benefits
Real-world studies from various countries consistently show cognitive and functional improvements in AD patients. However, here's where it gets interesting: the rate of amyloid-related imaging abnormalities seems lower in routine clinical practice compared to pivotal trials. This suggests that the benefits of these therapies might be even more significant in real-world settings.
The TRAILBLAZER-ALZ 2 study provides compelling evidence. Participants treated with donanemab for 18 months continued to show widening cognitive decline curves compared to the placebo group, even after 36 months. Moreover, those who achieved amyloid clearance maintained low amyloid levels, and the placebo group showed improved cognitive function upon switching to active treatment.
Trontinemab: A Rising Star?
Trontinemab, an experimental anti-amyloid monoclonal antibody developed by Roche, has captured significant attention. Updated data from phase 1b/2a trials show remarkable amyloid clearance, with 92% of participants receiving the highest dose falling below the amyloid-positivity threshold at 28 weeks. Additionally, reductions were observed in cerebrospinal fluid biomarkers associated with amyloid and tau pathologies.
Preliminary analyses suggest less cognitive decline compared to placebo, and the safety profile appears promising. However, the occurrence of hemorrhagic amyloid-related imaging abnormalities in a small percentage of participants raises questions. A phase 3 trial is currently underway to determine its clinical efficacy, but the initial results are certainly intriguing.
Semaglutide: A Disappointing Turn?
Semaglutide, a GLP-1 receptor agonist commonly used for obesity and type 2 diabetes, was evaluated for its potential disease-modifying effects on AD. Unfortunately, phase 3 findings did not demonstrate cognitive benefits. The evoke and evoke+ trials, which enrolled participants with early-stage AD, failed to show improvement in cognitive decline at 18 months, as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB).
While there were reductions in CSF biomarkers, including tau proteins and markers of neuroinflammation, the safety profile remained consistent with its use for other indications. This raises the question: is Semaglutide a promising candidate for AD treatment, or are we missing something crucial?
Anti-Tau Agents: A New Frontier
Bepranemab, an investigational humanized immunoglobulin G4 mAb targeting the tau protein, was evaluated in the phase 2 TOGETHER trial. While the study did not demonstrate a reduction in cognitive decline at 80 weeks, it did show a reduction in tau protein accumulation in AD patients. This is a significant development, as it opens up new avenues for AD treatment.
Another anti-tau mAb, etalanetug, was evaluated in a phase 1b/2a open-label study for autosomal dominant AD. Reductions in tau biomarkers were observed in both CSF and plasma, with impressive reductions of 78% and 90% at 2 years, respectively. Dr. Angioni emphasized the need for continued monitoring of this candidate.
The therapeutic landscape for Alzheimer's disease is rapidly evolving, and these developments offer both promise and controversy. As we continue to explore these avenues, what are your thoughts on the potential of these therapies? Do you think we're on the right track, or are there other approaches we should be considering? Share your insights and let's spark a conversation!
